Skip to the reading
IpamorelinIn Frame

What CJC-1295, Ipamorelin and IGF-1 cannot prove about a height increase after epiphyseal closure

If you’re asking whether an adult can become taller, the rat papers don’t establish that. Let’s separate the questions that tend to get bundled together.

First, the height question

Do the rat studies show that adults become taller?

No. Johansen’s experiment measured lengthwise bone growth in female rats. It didn’t test adult human height or treatment after human epiphyseal closure. That animal finding can’t establish a height benefit for a person.

Does more bone mineral mean stronger human bones?

Not from this study. The rat mineral paper found larger bones holding more mineral. Mineral density by volume, the amount for a given size, hadn’t changed.

The experiment didn’t measure fewer broken bones in people. Length, mineral content and strength are different questions, even when a claim groups them under “bone health.”

A blood test can seem like an easier way to answer the height question. But it needs the same careful reading.

Look closely at the bone findings

What a blood result can tell us

Did IGF-1 rise in the bone-growth study?

Total blood IGF-1 didn’t rise in that rat experiment. IGF-1 is a protein involved in growth. The bones grew faster without this blood measurement changing.

Can an IGF-1 test diagnose growth hormone deficiency?

Not on its own. FDA describes a diagnosis that needs the wider medical picture and usually tests that stimulate hormone release. A random growth hormone reading also can’t settle it alone.

For a visit, a useful question is what the result means in your situation. It needn’t lead straight to a request for a particular treatment.

One measurement doesn’t answer every question about growth. Adding another peptide doesn’t remove the need for the right evidence either.

See what a medical review involves

What about adding CJC-1295?

Has the combination proved a height benefit?

No human height benefit is established by these sources. The 2026 review discusses earlier research; it isn’t a human height trial. And the rat bone experiment tested Ipamorelin with a steroid, without CJC-1295. That experiment can’t tell us what adding CJC-1295 would do.

Was the steroid-and-bone experiment a combination study?

No. That adult-rat experiment added Ipamorelin to a steroid medicine called methylprednisolone. It didn’t test CJC-1295.

The distinction matters before that paper gets used to support a two-peptide claim. The FDA safety gaps for Ipamorelin remain relevant too.

Keep asking which preparation was tested, in whom, and for what outcome. Several promising words in one sentence don’t add up to a human result.

Open the sources